These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 30103765)
1. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study. Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765 [TBL] [Abstract][Full Text] [Related]
2. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial. Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190 [TBL] [Abstract][Full Text] [Related]
3. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391 [TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Wei Z; Zhang Z; Luo J; Li N; Peng X J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162 [TBL] [Abstract][Full Text] [Related]
5. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA. Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068 [TBL] [Abstract][Full Text] [Related]
6. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study. Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907 [TBL] [Abstract][Full Text] [Related]
7. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis. Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605 [TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538 [TBL] [Abstract][Full Text] [Related]
9. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma. Wang Q; Xu G; Xia Y; Zuo J; Zeng G; Xue Z; Cao R; Xiong W; Li W Oral Oncol; 2020 Dec; 111():104925. PubMed ID: 32721816 [TBL] [Abstract][Full Text] [Related]
10. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis. Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056 [TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis. He Y; Zhao Z; Wang Y; He J; Chai J; Wei Z; Guan H; Wang J; Liu Z; Li R; Mu X; He L; Peng X Clin Otolaryngol; 2021 Sep; 46(5):976-982. PubMed ID: 33821552 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study. Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148 [TBL] [Abstract][Full Text] [Related]
14. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma. Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878 [TBL] [Abstract][Full Text] [Related]
15. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era. Li PJ; Mo HY; Luo DH; Hu WH; Jin T Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326 [TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma. Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698 [TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma. Chen J; Liu T; Sun Q; Jin T Medicine (Baltimore); 2020 Jul; 99(29):e20443. PubMed ID: 32702809 [TBL] [Abstract][Full Text] [Related]
20. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma. Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]